Login / Signup

Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic.

Ulrike Tontsch-GruntPaula-Elena TraexlerAnke BaumHanny MusaKristell MarzinShaonan WangFrancesca TrapaniHarald EngelhardtFlavio Solca
Published in: British journal of cancer (2022)
BI 894999 holds significant potential as a combination drug and CCS1477 p300/CBP inhibitor is a promising partner for future clinical trials.
Keyphrases
  • clinical trial
  • primary care
  • current status
  • randomized controlled trial
  • emergency department
  • risk assessment
  • open label
  • drug induced
  • adverse drug
  • replacement therapy